ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1216

Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study

Rieke Alten1, William F. C. Rigby2, Alena Pechonkina3, Zhaoyu Yin4, Ken Hasegawa4, Thijs Hendrikx5, Tatsuya Atsumi6 and Rene Westhovens7, 1Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Gilead Sciences, Inc., Foster City, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos BV, Leiden, Netherlands, 6Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, 7University Hospitals Leuven, Belgium, Leuven, Belgium

Meeting: ACR Convergence 2020

Keywords: Patient reported outcomes, quality of life, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In FINCH 3, filgotinib (FIL)—a potent, selective, oral JAK1 inhibitor1—in combination with methotrexate (MTX), demonstrated significant improvements in signs and symptoms of rheumatoid arthritis (RA) vs MTX alone in patients (pts) who were MTX-naïve.2 For pts with RA, rapid control of pain and fatigue along with maintenance of physical function and health-related quality of life (HRQoL) are important outcomes.3 Patient-reported outcomes (PROs) can provide physicians with evidence to guide treatment decisions beyond guideline-recommended treatment targets of reducing immune inflammation to prevent joint damage, physical disability, and mortality.4 Here, we evaluated rate and magnitude of change in PROs assessing functional status, pain, HRQoL, and fatigue from FINCH 3 (NCT02886728).

Methods: Pts with active RA and MTX-naïve received FIL 200 mg daily+MTX, FIL 100 mg+MTX, FIL 200 mg+placebo (PBO), or MTX+PBO for up to 52 weeks. PROs, recorded prospectively, included HAQ-DI (functional status) and VAS pain scale (day 1, week [W]2, W4, W8, W12, W16, W20, W24, W30, W36, W44, W52), SF-36 (HRQoL), and FACIT-Fatigue (day 1, W4, W12, W24, W36, W52). The least squares mean of the change from baseline (CFB) at each time point up to W52 and p values (each FIL arm vs MTX) were analyzed using mixed-effects model for repeated measures.

For HAQ-DI, proportion of pts who achieved the minimum clinically important difference (MCID; reduction ≥0.22) between each FIL arm and MTX was analyzed using logistic regression analysis. P values for comparisons of PROs were not adjusted for multiplicity, except for HAQ-DI CFB at W24 for FIL 200 mg + MTX and FIL 100 mg + MTX vs MTX.

Results: Of 1249 pts randomized and treated (FIL 200 mg + MTX, n=416; FIL 100mg + MTX, n=207; FIL 200mg, n=210; MTX, n=416), 82.1% completed the study. Compared with MTX alone, a nominally significantly greater CFB in functional status and pain from W2 to W24 was observed in all FIL arms; the benefit was sustained from W30 to W52 (Fig 1). By W2, a nominally significantly greater proportion achieved the HAQ-DI MCID or greater (≥0.22) in all FIL arms (FIL 200 mg + MTX: 61.9%, p < 0.001; FIL 100 mg + MTX: 58.5%, p < 0.001; FIL 200 mg: 53.9%, p=0.004) compared with MTX (42.2%). By W8, ≥72% of pts in all FIL arms vs 63% of pts in the MTX arm achieved the HAQ-DI MCID; a numerically greater proportion of pts in FIL arms vs MTX achieved HAQ-DI MCID through W52. SF-36 physical component summary and FACIT-Fatigue scores were nominally significantly improved with FIL treatment vs MTX alone at various time points (Fig 2A, B). Improvements in SF-36 mental component summary scores were nominally significant for pts in all FIL arms vs MTX alone as early as W4, and the CFB reached at W12 for FIL arms was generally sustained up to W52 (Fig 2A).

Conclusion: For pts with moderate to severe RA who were MTX-naïve, FIL—with or without concomitant MTX—led to rapid and sustained improvements in functional status, pain, fatigue, and HRQoL, compared with MTX alone.

References

  1. Van Rompaey, et al. J Immunol. 2013;131:3568–77.
  2. Westhovens, et al. Arthritis Rheumatol. 2019;71 (suppl 10):1606–8.
  3. Fautrel B, et al. Rheumatol Int. 2018;38:935–47.
  4. Smolen JS, et al. Ann Rheum Dis. 2017;76:960–77.


Disclosure: R. Alten, Pfizer, 2, 8, Gilead Sciences, Inc., 2, Novartis, 2, AbbVie, 2, 5, Bristol-Myers Squibb, 2, 5, Lilly, 2, 5, UCB, 2, 5; W. Rigby, Gilead Sciences, Inc., 5; A. Pechonkina, Gilead Sciences, Inc., 1, 3; Z. Yin, Gilead Sciences, Inc., 1, 3; K. Hasegawa, Gilead Sciences, Inc., 1, 3; T. Hendrikx, Galapagos, 1, 3; T. Atsumi, AbbVie Inc., 5, 8, 9, UCB Japan Co.,Ltd., 5, 8, Eisai Co., Ltd., 8, Gilead Sciences, Inc., 5, 8, Bristol Myers Squibb Co., 2, 8, Chugai Pharmaceutical Co., Ltd., 2, 8, 9, Mitsubishi Tanabe Pharma Corporation, 8, 9, Eli Lilly Japan K.K., 2, 5, 8, Astellas Pharma Inc., 8, 9, Pfizer Inc., 2, 8, 9, Daiichi Sankyo Company, Limited, 5, 8, 9; R. Westhovens, Celltrion, Inc., 2, 5, Galapagos NV, 2, 5, Gilead Sciences, Inc., 2, 5.

To cite this abstract in AMA style:

Alten R, Rigby W, Pechonkina A, Yin Z, Hasegawa K, Hendrikx T, Atsumi T, Westhovens R. Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/filgotinib-provided-rapid-and-sustained-improvements-in-functional-status-pain-and-health-related-quality-of-life-and-reduced-fatigue-over-time-in-patients-with-rheumatoid-arthritis-who-are-methotr/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/filgotinib-provided-rapid-and-sustained-improvements-in-functional-status-pain-and-health-related-quality-of-life-and-reduced-fatigue-over-time-in-patients-with-rheumatoid-arthritis-who-are-methotr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology